A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of KW-2450 in Combination With Lapatinib and Letrozole in Subjects With Advanced or Metastatic Breast Cancer Whose Tumors Overexpress HER2.
Phase of Trial: Phase I/II
Latest Information Update: 03 Jun 2014
At a glance
- Drugs KW 2450 (Primary) ; Lapatinib; Letrozole
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Kyowa Hakko Kirin
- 10 Jan 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 12 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 06 Dec 2010 Actual initiation date (Dec 2010) added as reported by ClinicalTrials.gov.